News

REACH Incubator Project - First Open Call for Startups and SMEs - webinar on 26.01

Published on | 4 years ago

Programmes ICT SME Instrument

The European Commission funded the H2020 project project "REACH" (EuRopEAn incubator for trusted and secure data value Chains). REACH will support selected data-fuelled start-ups & SMEs through a 11-month incubation programme facilitating the development of trusted and secure innovative solutions based on industrial and personal data. 

Specifications:

  • Single applicants only.
  • Funding: up to 120000€ in equity free funding
  • Your legal business must be based in a European Member State, Associated Country and be eligible for Horizon 2020 programmes.

Applying can be done by clicking here - deadline February 15th, 2021 at 12:00 (noon) CET

When applying, please inform NCP advisor Magali.parent@vlaio.be.

A webinar about the application process and what you can expect from the incubation programme will be organized on January 26th, 13:00 CET. All details and registration can be found here.

 

 

 

 

 

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1664 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.